Header Image

Navigation

Subnavigation

Invest in the Medicines of Tomorrow

MorphoSys is a profitable growth company, building a strong therapeutic antibody pipeline with more than 60 projects in development, mainly in partnerships, but also increasingly for its own account. With total operating revenues of € 81 million in 2009, an organic increase of 13 percent from 2008, MorphoSys will participate in successful drug development by its partners through milestone and future royalty payments for marketed HuCAL-based drugs.

Events

Next events
  1. 03/23/2010 Kempen & Co Life Sciences Conference
  2. 05/03/2010 Deutsche Bank's 35th Annual Health Care Conference
  
 
Press Releases
Ad Hocs
  1. 02/25/2010MorphoSys AG Reports Positive Results for Fiscal Year 2009
  2. 02/23/2010AbD Serotec Significantly Improves Antibody Generation Process
  1. 12/02/2007Ad hoc: 2-MorphoSys Financial Guidance 2007 Under Review
  2. 12/02/2007Ad hoc: 1-MorphoSys and Novartis Forge New Strategic Alliance to Establish Innovative Therapeutic Antibody Pipeline
  
Reports
Conference Calls
Presentations
  1. Consolidated Financial Statements (IFRS) 2009
  2. Nine Months’ Report 2009
  3. More…
  1. YE 2009, MP3 13.0 MB
  2. Q3 2009, MP3 6.0 MB
  3. More…
  1. Year-end 2009 and Q4 Results
  2. WestLB Deutschland Conference 2009
  3. More…
 

Quicklinks

  

Order service